Evidence map›Paper›PMID 37383059›Full record

ArticleJournal of liver cancer2020

Recurrent Coronary Artery Vasospasm in a Patient with Hepatocellular Carcinoma Treated with Sorafenib: a Case Report and Literature Review.

Dae Hyun Lim, Jai Hoon Yoon, Dae Won Jun, Oh Young Lee, Byung Chul Yoon, Hang Rak Lee, Kyung Soo Kim, Ho Soon Choi

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of liver cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Vascular Toxicities of Cancer Therapies: 2025 Update.Arteriosclerosis, thrombosis, and vascular biology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Dae Hyun LimDivision of Gastroenterology, Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.
Jai Hoon YoonDivision of Gastroenterology, Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.
Dae Won JunDivision of Gastroenterology, Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.
Oh Young LeeDivision of Gastroenterology, Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.
Byung Chul YoonDivision of Gastroenterology, Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.
Hang Rak LeeDivision of Gastroenterology, Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.
Kyung Soo KimDivision of Cardiology, Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.
Ho Soon ChoiDivision of Gastroenterology, Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.ORCID 0000-0003-3746-8742
Hanyang University · KRUniversity Gastroenterology · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tyrosine kinase inhibitors are widely used as targeted treatments for various malignancies. Sorafenib is an orally active tyrosine kinase inhibitor that blocks the signaling pathways of several growth factors. Its use is approved for various malignancies such as unresectable hepatocellular carcinoma, renal cell carcinoma, and gastrointestinal stromal tumors. Several adverse effects have been reported in the literature; however, cardiotoxicity is rare. We present a case of recurrent coronary vasospasm caused by short-term administration (5 days) of sorafenib. Since it caused refractory ischemia after re-administration, we had no choice but to stop the treatment.

Indexed as

Coronary artery vasospasmSorafenibTyrosine kinase inhibitorVariant anginaVascular endothelial growth factor inhibitor

Identifiers

PMID37383059
PMCPMC10035694
OpenAlexW3014592863

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.